CSDGX Performance — Copeland SMID Cap Dividend Growth Fund, Class A
Data updated: 2026-07-24
CSDGX returned +10.94% year to date and +16.90% over one year to May 2026. Annualised returns are +9.47% over 3 years and +4.57% over 5 years. The fund trailed its US Mid-Cap Value category average: $100 invested three years ago grew to $131, against $154 for the category, and to $117 over one year, against $121. Volatility over the past three years was 16.52% a year. In the 12 months to May 2026 the fund lost a net $35.9M, and assets reached $138.87M.
CSDGX Growth of $100
What $100 invested in Copeland SMID Cap Dividend Growth Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Mid-Cap Value category average over the same months.
| Period | CSDGX | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $117 | $121 |
| 3 years (Jun 2023 – May 2026) | $131 | $154 |
| 5 years (Jun 2021 – May 2026) | $125 | $148 |
| Since data start (Mar 2020 – May 2026) | $168 | $217 |
CSDGX Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +10.94% |
| 1 year | +16.90% |
| 3 years (annualised) | +9.47% |
| 5 years (annualised) | +4.57% |
CSDGX Annual Returns
Calendar-year total returns of Copeland SMID Cap Dividend Growth Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | +10.94% |
| 2025 | +2.53% |
| 2024 | +1.94% |
| 2023 | +18.53% |
| 2022 | −14.99% |
| 2021 | +22.15% |
| 2020 (Mar–Dec) | +17.73% |
CSDGX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +5.6% | +5.2% | −6.6% | +5.8% | +1.0% | — | — | — | — | — | — | — |
| 2025 | +2.5% | −2.9% | −4.3% | −2.4% | +4.7% | +3.1% | −0.1% | +4.4% | −2.3% | −1.5% | +2.9% | −1.1% |
| 2024 | −2.5% | +5.0% | +3.5% | −6.8% | +2.8% | −0.5% | +7.5% | −1.0% | +0.3% | −2.1% | +6.7% | −9.6% |
| 2023 | +10.5% | −2.3% | −1.4% | +0.2% | −1.8% | +8.5% | +2.5% | −3.1% | −4.8% | −5.8% | +7.6% | +8.8% |
| 2022 | −7.1% | +1.0% | +1.1% | −6.9% | +2.2% | −8.4% | +10.3% | −4.9% | −8.7% | +9.6% | +4.0% | −5.9% |
| 2021 | −0.1% | +5.0% | +4.5% | +4.3% | −0.2% | +0.1% | +0.5% | +1.6% | −3.3% | +4.9% | −2.4% | +5.7% |
| 2020 | — | — | −17.3% | +10.9% | +6.6% | +0.7% | +4.7% | +0.4% | −1.9% | +0.7% | +10.4% | +4.3% |
CSDGX Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 16.52%
- 3-year Sharpe ratio: 0.30 (vs 4.5% risk-free rate)
- Best month: +8.84% (Dec 2023)
- Worst month: −9.57% (Dec 2024)
CSDGX Fund Flows
Monthly money in and out of Copeland SMID Cap Dividend Growth Fund, from SEC Form N-PORT.
- 12-month net flow: −$35.9M
- 12-month gross sales (incl. reinvestments): $74.4M
- Sales ÷ redemptions: 0.67×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $1.1M | $1.7M | −$511K |
| Apr 2026 | $1.2M | $4.9M | −$3.7M |
| Mar 2026 | $1.8M | $5.8M | −$4.1M |
| Feb 2026 | $2.2M | $2.6M | −$431K |
| Jan 2026 | $2.2M | $31.4M | −$29.2M |
| Dec 2025 | $8.3M | $2.6M | $5.7M |
| Nov 2025 | $1.8M | $5.6M | −$3.9M |
| Oct 2025 | $2.4M | $3.0M | −$549K |
| Sep 2025 | $1.7M | $6.8M | −$5.1M |
| Aug 2025 | $4.5M | $3.4M | $1.1M |
| Jul 2025 | $42.6M | $38.8M | $3.7M |
| Jun 2025 | $4.5M | $3.5M | $957K |
CSDGX Assets Under Management
Net assets of Copeland SMID Cap Dividend Growth Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $138.87M |
| 2026-02-28 | $147.78M |
| 2025-11-30 | $161.94M |
| 2025-08-31 | $173.10M |
| 2025-05-31 | $155.33M |
| 2025-02-28 | $178.04M |
| 2024-11-30 | $199.67M |
| 2024-08-31 | $183.75M |
| 2024-05-31 | $160.31M |
| 2024-02-29 | $112.63M |
| 2023-11-30 | $68.28M |
| 2023-08-31 | $67.65M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.